Back to Search
Start Over
Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
- Source :
- Central-European Journal of Immunology
- Publication Year :
- 2017
- Publisher :
- Termedia Sp. z.o.o., 2017.
-
Abstract
- Although previous decades contributed to major progress in targeted therapy of many malignancies, the treatment of gynaecological cancers remains a challenging task. In the evidence of rising cancer mortality, the search for new methods of treatment is a dire need. Exploring the mechanisms of interaction between tumour cells and host immune response may allow the introduction of new, effective therapies – not as toxic and far more efficient than conventional methods of cancer treatment. Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages. Its incidence and mortality rate is high. Powerful diagnostic tools for this kind of cancer are still under investigation. Multiple mechanisms existing in the ovarian tumour network create a specific immunosuppressive microenvironment, in which accumulation of myeloid-derived suppressor cells (MDSCs) may be a critical component for diagnosis and treatment. This review attempts to verify current knowledge on the role of MDSCs in EOC.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
Immunology
T cells
law.invention
Targeted therapy
03 medical and health sciences
0302 clinical medicine
Immune system
law
Immunology and Allergy
Medicine
Review Paper
business.industry
Mortality rate
Cancer
medicine.disease
Cancer treatment
ovarian cancer
030104 developmental biology
030220 oncology & carcinogenesis
Myeloid-derived Suppressor Cell
Cancer research
Suppressor
business
Ovarian cancer
myeloid-derived suppressor cells (MDSCs)
Subjects
Details
- ISSN :
- 14263912
- Volume :
- 42
- Database :
- OpenAIRE
- Journal :
- Central European Journal of Immunology
- Accession number :
- edsair.doi.dedup.....f22cb0326fad7727d6569f124a234559